Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S
Open Access
- 18 November 2025
- journal article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (11) , e70118
Abstract
Background: Hereditary angioedema (HAE‐C1INH) attacks involving mucosal tissue may progress rapidly and often lead to substantial morbidity. Severe laryngeal attacks can be fatal without prompt administration of on‐demand treatment. This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2‐year, open‐label extension KONFIDENT‐S study (NCT05505916). Methods: Eligible participants ≥ 12 years with HAE‐C1INH self‐administered sebetralstat 600 mg film‐coated tablets with an optional second dose after 3 h, if warranted. Primary outcome: incidence of treatment‐emergent adverse events (TEAEs). Secondary outcomes: times to beginning of symptom relief, reduction in severity, and complete resolution. Results: At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat. Seven (43.8%) participants with laryngeal attacks experienced 14 TEAEs whereas 36 (35.3%) participants with abdominal attacks experienced 91 TEAEs. No difficulty swallowing sebetralstat was reported. Median (IQR) time to treatment: 11.5 min (1.0–34.0) and 20.0 min (1.0–61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76–3.02) and 1.27 h (0.76–3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24). Most mucosal attacks that achieved beginning of symptom relief within 12 h did so with a single dose of sebetralstat (laryngeal: 96.0%; abdominal: 95.8%). Conventional on‐demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks. Conclusion: Oral sebetralstat enabled rapid treatment of laryngeal and abdominal attacks of all severities, was well tolerated, and provided early symptom relief.Keywords
Funding Information
- KalVista Pharmaceuticals
This publication has 30 references indexed in Scilit:
- Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trialAnnals of Allergy, Asthma & Immunology, 2014
- Nanofiltered C1 Esterase Inhibitor for Treatment of Laryngeal Attacks in Patients with Hereditary AngioedemaAmerican Journal of Rhinology & Allergy, 2013
- Analysis of hereditary angioedema attacks requiring a second dose of ecallantideAnnals of Allergy, Asthma & Immunology, 2013
- Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacksAnnals of Allergy, Asthma & Immunology, 2013
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012
- C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 studyAllergy, 2011
- Hereditary AngioedemaNew England Journal of Medicine, 2008
- Symptoms, Course, and Complications of Abdominal Attacks in Hereditary Angioedema Due to C1 Inhibitor DeficiencyAmerican Journal of Gastroenterology, 2006
- C1 inhibitor deficiency: consensus documentClinical and Experimental Immunology, 2005
- Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary AngioedemaJournal of Allergy and Clinical Immunology, 2004